Company: BGLC
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001477932-25-008343
Chunk: 25

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 25
---
,604 Renovation  111,519   101,137 Signboard  806   806 Solar PV System  16,935   16,935 Machinery  211,898   190,341    2,541,732   2,506,143 (Less): Accumulated depreciation  (840,419 )  (756,976 )(Less): Accumulated impairment  (40,173 )  (40,173 )Add: Foreign translation differences  (90,556 )  (186,004 )Property, plant and equipment, net $1,570,584  $1,522,990  During the nine month period ended September 30, 2025 and 2024, the Company recorded depreciation of $83,443 and $74,611, respectively. 

 20Table of Contents

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024 

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

NOTE 7 – INVESTMENTS IN EQUITY SECURITIES   As of   September 30,  December 31,   2025  2024 As of beginning of the period/year $1,265,166  $1,699,831 Addition during the period/year  9,064   492,732 Disposal during the period/year  (993,955)  (1,030,368 )Fair value (loss)/gain  (91,243 )  69,476 Foreign exchange translation   48,728   33,495 As of end of the period/year $237,760  $1,265,166  For the nine month period ended September 30, 2025 and 2024, respectively, the net fair value (loss)/gains on the investments in equity securities were $(91,243) and $63,650 recorded in administrative expenses and other income of the Consolidated Statements of Operations and Comprehensive Income/(Loss).   The investments in equity securities consist of the following shares:         As of   September 30,  December 31,